No Data
No Data
Morgan Stanley Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $55
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Ionis Pharmaceuticals (IONS) and Amicus (FOLD)
Wolfe's Tax Loss Selling Stocks Within Communications, Discretionary, Staples, Energy, Financials, Health Care
Guggenheim Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Raises Target Price to $65
Express News | Ionis Pharmaceuticals Inc : Guggenheim Cuts Target Price to $65 From $70
Laidlaw Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $68